ACHE predesign siRNA
- Known as:
- ACHE predesign small interfearing RNA
- Catalog number:
- RI10058
- Product Quantity:
- 5 OD
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- ACHE predesign siRNA
Related genes to: ACHE predesign siRNA
- Gene:
- ACHE NIH gene
- Name:
- acetylcholinesterase (Cartwright blood group)
- Previous symbol:
- YT
- Synonyms:
- -
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-02
- Date modifiied:
- 2019-04-23
Related products to: ACHE predesign siRNA
Related articles to: ACHE predesign siRNA
- Terminally ill immigrant patients may wish to return to their homeland to die. However, the challenges and repatriation experiences faced by terminally ill Latinx immigrants who return to their country of origin (COO) remain underexplored. This study examines bereaved caregiver accounts of end-of-life (EOL) care and repatriation experiences of Latinx immigrants who returned to their COO following a terminal diagnosis. - Source: PubMed
Publication date: 2026/06/05
Flores Ana IHeller Frances EichholzDinicu Andreea IAngel FionaHou JuneMaciejewski PaulPrigerson HollyBlinderman Craig DavidTergas Ana I - The P2Y receptor (P2YR) is a G protein-coupled receptor (GPCR) that can be activated by the extracellular nucleotide uridine diphosphate glucose (UDPG). It performs crucial regulatory roles in diverse pathophysiological contexts, such as immune modulation, inflammatory responses, tumor progression, and metabolic disorders. Therefore, it represents a highly attractive therapeutic target. This review elucidates the signal transduction mechanism of P2YR and its pathological functions in conditions such as gouty arthritis (GA) and neuropathic pain (NP). Meanwhile, P2YR inhibitors based on multiple drug discovery strategies are also comprehensively summarized. Furthermore, this review analyzes the key challenges currently faced in inhibitors research and development. By integrating the latest reported crystal structure of P2YR, it looks forward to the prospects of precise drug design based on structure and clinical translation. This provides a theoretical basis and innovative direction for the future development of P2YR-targeted therapeutic drugs. - Source: PubMed
Publication date: 2026/06/05
Ren ShufanWang KaiWang JialiangXie JiatongZhou JiayiHou WenjieTong RuiqingHu QinghuaLi Huanqiu - Mesenchymal stromal cells (MSCs) have the capacity to self-renew and exert immunomodulatory and paracrine effects. Our previously published systematic review of 55 randomized controlled trials (RCTs) of all MSC sources found an overall favorable safety profile for MSCs aside from more frequent fever in the MSC group. - Source: PubMed
Hum ChristinePoliwoda JessicaLalu ManojStewart Duncan JMei Shirley H JWalley Keith RMarshall JohnMendelson Asher AFergusson Dean AEnglish ShaneWinston Brent WGranton JohnDos Santos Claudia CChampagne JoseeMcIntyre Lauralyn - Dental pulp is a densely innervated, low-compliance tissue in which neurogenic inflammation can rapidly escalate into oedema, raised intrapulpal pressure, microvascular compromise, and pain. While Substance P (SP) and Calcitonin gene-related peptide (CGRP) are well-established drivers of pulp vasodilation, the Neuroopeptide Y (NPY) endogenous counter-regulatory mechanism remain comparatively under-explored. - Source: PubMed
Publication date: 2026/06/05
Caviedes-Bucheli JavierUlate EstebanMunoz Hugo-RobertoRíos-Osorio Nestor - Cavernous sinus thrombosis (CST) is a rare and life-threatening neuro-ophthalmologic emergency. The role of adjunctive anticoagulation in infection-driven CST-especially when patients respond rapidly to antibiotics-remains a clinically significant dilemma. We report the case of a 50-year-old male presenting with acute right periorbital swelling, proptosis, ocular pain, and headache. Magnetic resonance imaging (MRI) confirmed right cavernous sinus thrombosis secondary to bilateral sinusitis. After multidisciplinary review, anticoagulation was withheld due to the patient's prompt clinical improvement on targeted intravenous antibiotics (meropenem/ertapenem) and concerns regarding bleeding risk. Complete symptomatic and radiological recovery was achieved, as evidenced by serial MRI follow-up over eight months. This case demonstrates that in selected patients with septic CST and a treatable infectious source, aggressive antibiotic therapy alone may lead to full resolution. It highlights the value of individualized management and contributes to the ongoing discussion on the timing and necessity of anticoagulation in this complex condition. - Source: PubMed
Publication date: 2026/05/20
Wang Xiao-OuHu Cui-ZhuNiu Yi-MengTian Wen